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Abstract
Introduction: Conventional markers of acute kidney injury (AKI) lack diagnostic accuracy and are expressed only
late after cardiac surgery with cardiopulmonary bypass (CPB). Recently, interest has focused on hepcidin, a
regulator of iron homeostasis, as a unique renal biomarker.
Methods: We studied 100 adult patients in the control arm of a randomized, controlled trial http://www.
clinicaltrials.gov/NCT00672334 who were identified as being at increased risk of AKI after cardiac surgery with CPB.
AKI was defined according to the Risk, Injury, Failure, Loss, End-stage renal disease classification of AKI classification
stage. Samples of plasma and urine were obtained simultaneously (1) before CPB (2) six hours after the start of CPB
and (3) twenty-four hours after CPB. Plasma and urine hepcidin 25-isoforms were quantified by competitive
enzyme-linked immunoassay.
Results: In AKI-free patients (N = 91), urine hepcidin concentrations had largely increased at six and twenty-four
hours after CPB, and they were three to seven times higher compared to patients with subsequent AKI (N =9 )i n
whom postoperative urine hepcidin remained at preoperative levels (P = 0.004, P = 0.002). Furthermore, higher
urine hepcidin and, even more so, urine hepcidin adjusted to urine creatinine at six hours after CPB discriminated
patients who did not develop AKI (area under the curve (AUC) receiver operating characteristic curve 0.80 [95%
confidence interval (95% CI) 0.71 to 0.87] and 0.88 [95% CI 0.78 to 0.97]) or did not need renal replacement
therapy initiation (AUC 0.81 [95% CI 0.72 to 0.88] 0.88 [95% CI 0.70 to 0.99]) from those who did. At six hours, urine
hepcidin adjusted to urine creatinine was an independent predictor of ruling out AKI (P = 0.011). Plasma hepcidin
did not predict no development of AKI. The study findings remained essentially unchanged after excluding
patients with preoperative chronic kidney disease.
Conclusions: Our findings suggest that urine hepcidin is an early predictive biomarker of ruling out AKI after CPB,
thereby contributing to early patient risk stratification.
Introduction
Acute kidney injury (AKI) associated with cardiopul-
monary bypass (CPB) is relatively common and carries
significantly increased morbidity, mortality and cost [1].
It is now the second most common cause of severe AKI
in critically ill patients [2]. Its pathogenesis is complex
[3], and the development of targeted new treatments is
likely to depend on early diagnosis. Unfortunately, con-
ventional markers of AKI, such as serum creatinine,
serum urea and urine output, lack diagnostic sensitivity
and specificity and often identify patients with AKI only
24 or 48 hours after surgery [4-6]. Accordingly, progress
in this field is likely to depend, at least in part, on the
availability of novel biomarkers for early and reliable
diagnosis of AKI.
Over the past decade a number of early markers of
AKI have been identified using genomic [7,8] and pro-
teomic [9] laboratory methods. These biomarkers may
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[5,6]. More recently, interest has focused on hepcidin as
a regulator of iron homeostasis [10]. The hepcidin gene
is regulated by iron loading, hypoxia or inflammation
[10-12], and its protein is produced by liver and kidney
cells [13]. In a pilot study of a nested cohort of 22
patients with AKI and 22 without AKI, Ho et al. [14]
reported a greater postoperative signal/noise ratio for
urine hepcidin levels in those patients who did not go
on to develop AKI, suggesting that hepcidin may be the
first clinically useful negative biomarker for AKI after
CPB.
Accordingly, we investigated the association of urine
and plasma hepcidin levels in patients undergoing car-
diac surgery with the use of CPB. We aimed to (1)
assess the predictive value of early postoperative urine
hepcidin and plasma hepcidin for ruling out AKI, (2)
investigate the role of chronic kidney disease (CKD) on
the predictive value of hepcidin and (3) explore whether
changes in urine hepcidin reflect changes in plasma
hepcidin.
Materials and methods
Patient population
For the purpose of our study, we investigated all 100
adult patients of the German study site (German Heart
Center Berlin) enrolled into the control arm of the
Sodium Bicarbonate in Cardiac Surgery Study http://
www.clinicaltrials.gov/NCT00672334, a multicenter, ran-
domized, controlled trial of perioperative sodium bicar-
bonate versus placebo for the prevention of AKI and the
exploration of renal biomarkers in patients at increased
renal risk undergoing cardiac surgery necessitating the
use of CPB. Increased risk of AKI was defined as at
least one risk factor for postoperative AKI: age ≥70
years; New York Heart Association class III/IV or left
ventricular ejection fraction (LVEF) <35%; insulin-
depending diabetes mellitus; prior cardiac surgery; valv-
ular surgery (with or without coronary artery bypass
graft) or preoperative serum creatinine >120 μmol/L.
We excluded patients undergoing emergency opera-
tions (time between hospital admission to operation ≤24
hours) or off-pump surgery, patients presenting with
advanced CKD (serum creatinine >300 μmol/L) or kid-
ney transplant and patients <18 years old. Clinical prac-
tice was not changed or modified for the purpose of the
study.
CKD was defined as preoperative estimated glomeru-
lar filtration rate (eGFR) <60 mL/minute/1.73 m
2 [15].
eGFR was estimated using the Modification of Diet in
Renal Disease Study equation reexpressed for use with
the serum creatinine values standardized to isotope dilu-
tion mass spectroscopy [16]. Renal replacement therapy
(RRT) was initiated if the patient fulfilled at least one of
the following clinical criteria: oliguria (urine output
<100 mL/>6 hours) that was unresponsive to fluid
resuscitation measures, hyperkalemia (potassium >6.5
mmol/L), severe acidosis (pH <7.2) or clinically signifi-
cant organ edema (for example, lung) in the setting of
renal failure.
Samples were obtained from 100 patients enrolled in
the placebo group (sodium chloride 1.2 L starting with
anesthesia induction and finishing 24 hours thereafter).
Patients were recruited between January 2009 and June
2010. The local Institutional Review Board approved
this investigation, and written, informed consent was
obtained from each patient, including the investigation
of novel renal biomarkers. The study was carried out in
compliance with the Declaration of Helsinki.
Sampling
Samples of plasma and urine were obtained simulta-
neously (1) directly after insertion of an arterial line
(baseline) before induction of anesthesia, (2) at 6 hours
after commencement of CPB and (3) at 24 hours after
commencement of CPB. The timing of sampling was
chosen to detect renal biomarkers before serum creati-
nine increases and was therefore limited to the first 24
hours postoperatively. Aliquots of plasma and urine
were frozen and stored at -80°C immediately after col-
lection and centrifugation and were kept frozen on dry
ice during transport.
Data collection and outcome definition
Demographic and clinical data (Table 1) were collected
at baseline and for the first 48 hours. Serum creatinine
was measured at baseline, at 6 and 24 hours after com-
mencement of CPB, daily within the first postoperative
week and, if required, until hospital discharge. The pri-
mary outcome, AKI, was defined based on the baseline-
to-peak serum creatinine increase (>50%) or urine out-
put decrease (<0.5 ml/kg/hr for at least 6 hours) during
the first seven postoperative days using the Risk, Injury,
Failure, Loss, End-stage renal disease classification of
AKI (RIFLE) consensus definition of AKI [17,18]. Addi-
tional analyses were performed to assess the ability of
hepcidin to predict the severity of AKI using RIFLE
classes R, I and F and the need for RRT initiation. The
Strengthening the Reporting of Observational Studies in
Epidemiology guidelines [19] for reporting observational
studies were used.
Biochemical analysis
Coinvestigators performing hepcidin assays were blinded
to patient details and AKI classification. Human urine
and plasma hepcidin 25-isoforms were measured by
competitive enzyme-linked immunoassay, as previously
described [20], by Intrinsic LifeSciences LLC (La Jolla,
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ng/mL. The median coefficients of variation were 10%
for intraassay precision and 6% for interassay reproduci-
bility. Hepcidin stability during sample storage was
tested prior to this study with median change in hepci-
din concentrations in plasma <5% and in urine <6%
after six months at -80°C. For the purposes of this
study, samples were assayed after storage at -80°C. Hep-
cidin values are expressed as nanograms per milliliter.
To compensate for perioperative variation in urine dilu-
tion, urine hepcidin adjusted to urine creatinine was cal-
culated and expressed as nanograms of hepcidin per
milligram of creatinine. Serum creatinine assays were
carried out by Austin Health pathology services (Mel-
bourne, Australia) using the modified Jaffé method.
Fractional excretion (FE) of hepcidin, that is, the pro-
portion of filtered hepcidin that appears in urine, was
calculated using the following formula:
FEhepcidin =( [ U hepcidin] × [Plcreat]/[Plhepcidin] × [Ucreat]) × 100%,
where Uhepcidin = urine hepcidin concentration, Plhepci-
din = plasma hepcidin concentration, Plcreat =p l a s m a
creatinine concentration and Ucreat = urine creatinine
concentration.
Statistical analysis
Statistical analysis was performed using SPSS version
16.0 software (SPSS Inc., Chicago, IL, USA) and Med-
Calc 11.5 software (Mariakerke, Belgium). Categorical
data were reported as percentages with 95% confidence
intervals (95% CIs) of the mean percentage and were
compared using Fisher’s exact test. After testing for nor-
mal distribution, continuous data were reported as med-
ians with 25th to 75th percentiles, and nonparametric
data were compared using the Mann-Whitney U test.
Continuous data over time were compared using the
one-way repeated measures analysis of variance by ranks
(Friedman test). We used nonparametric bivariate corre-
lation and report Spearman correlation coefficients (r).
The ability of hepcidin to predict AKI was assessed by
plotting receiver operating characteristic (ROC) curves
and further reported as areas under the curve (AUC)
with 95% CIs. An AUC-ROC value of >0.7 was taken to
indicate reasonable biomarker performance and >0.8
was taken to indicate good biomarker performance [21].
An AUC-ROC difference >0.1 units between biomarkers
was defined as significant. ROC curve optimal cutoff
values for AKI diagnosis, for curves with a statistically
significant AUC, were defined as the point that maxi-
mized the Youden index, defined as (sensitivity + speci-
ficity) - 1 [22]. The increased discriminative value of the
biomarkers regarding the composite end point was stu-
died by assessing the net reclassification improvement
(NRI) as described by Pencina et al. [23]. Univariate and
multivariate stepwise regression analyses were underta-
ken to assess predictors of no AKI after CPB. Variables
tested on univariate relation with incidence of no AKI
included clinically relevant variables, all of which are
displayed in Table 1 as well as the type and duration of
surgery and renal biomarkers at six hours after the start
Table 1 Characteristics of patients developing AKI compared with those who did not develop AKI
All Patients Excluding Patients With
Preoperative CKD
Variables AKI
N =9
No AKI
N =9 1
P value AKI
N =5
No AKI
N =6 9
P value
Age, y 74 (70-77) 67 (56-73) 0.015 75 (73-84) 65 (55-72) 0.003
Female, n 2 (22.2%) 31 (34.1%) 0.47 1 (20.0%) 19 (27.5%) >0.99
Preoperative eGFR, mL/min/1.73 m
2 61 (52-91) 74 (62-88) 0.58 86 (72-100) 80 (70-92) 0.52
Preoperative CKD, n 4 (44.5%) 22 (24.2%) 0.23 - - -
LVEF <35%, n 3 (33.3%) 8 (8.8%) 0.06 1 (20.0%) 6 (8.7%) 0.40
Atrial fibrillation 6 (66.7%) 25 (27.5%) 0.015 4 (80.0%) 18 (26.1%) 0.025
Arterial hypertension 8 (88.9%) 65 (71.4%) 0.26 5 (100.0%) 48 (69.6%) 0.31
COPD 3 (33.3%) 8 (8.8%) 0.025 2 (40.0%) 6 (8.7%) 0.087
Diabetes mellitus, n 3 (33.3%) 17 (18.7%) 0.38 0 (0.0%) 12 (17.4%) 0.58
PVD, n 4 (44.5%) 17 (18.7%) 0.09 2 (40.0%) 11 (15.9%) 0.21
AKI, acute kidney disease; AKI defined as RIFLE class R or worse including serum creatinine increase and urine output decrease.
Diabetes mellitus defined as diabetes on medication (insulin or oral antidiabetics).
CKD, chronic kidney disease; COPD, chronic obstructive pulmonary disease; eGFR, estimated glomerular filtration rate; LVEF, left ventricular ejection fraction;
PVD, peripheral vascular disease.
Median (25
th to 75
th percentiles).
aAKI, acute kidney injury; CKD, chronic kidney disease; COPD, chronic obstructive pulmonary disease; eGFR, estimated glomerular filtration rate; LVEF, left
ventricular ejection fraction; PVD, peripheral vascular disease. AKI is defined as Risk, Injury, Failure, Loss, End-stage renal disease classification of AKI (RIFLE) class
R or worse, including serum creatinine increase and urine output decrease. Diabetes mellitus is defined as patients with diabetes on medication (insulin or oral
antidiabetics). Data are medians (25th to 75th percentiles) unless otherwise indicated.
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included clinically relevant variables with a univariate P
value <0.1 (age, atrial fibrillation, LVEF <35%, chronic
obstructive pulmonary disease [COPD], peripheral vas-
cular disease [PVD]) and renal biomarkers. Logarithmic
transformations were applied when necessary before
multivariable logistic regression analyses were per-
formed. Statistical significance was denoted by two-
sided P values <0.05.
Results
Sampling
Figure 1 shows the patient flow through the study.
Three hundred ninety-four consecutive patients were
screened according to the inclusion and exclusion cri-
teria. Of those, 200 patients were randomized, with all
of them undergoing surgery as planned. Of the 100 con-
trol patients (analyzed cohort on hepcidin), all had full
clinical data sets and complete sampling, except in two
patients (no AKI) from whom plasma and urine samples
could not be collected at 24 hours after CPB.
Patient characteristics
Compared with patients with postoperative AKI, AKI-
free patients (n = 91) were younger and less frequently
had preoperative atrial fibrillation and COPD (Table 1).
Type and duration of operation did not differ between
patients with postoperative AKI and those without,
whereas perioperative fluid balance, dose of furosemide
and volume of red blood cell transfusion were lower
and outcomes were better, including less frequent need
for RRT initiation, in AKI-free patients (Table 2). Of
patients with AKI, RRT was initiated in three cases, and
in those without AKI, RRT was commenced in two
patients, in both cases due to anuria for less than six
hours and preoperative CKD.
Urine hepcidin
Starting with a nonsignificant difference at baseline, at
six hours and at twenty-four hours after commencement
of CPB, urine hepcidin levels were significantly higher in
AKI-free patients (Figure 2A). AUC-ROC curves for
urine hepcidin at six hours for the discrimination of
Figure 1 Patient flow through the study http://www.clinicaltrials.gov/NCT00672334. CPB, cardiopulmonary bypass.
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ure 4A). Further, the negative predictive value for not
developing AKI was 96.3% and the positive predictive
value was 31.6%. At six hours, the NRI of urine hepcidin
for ruling out AKI was 17% compared to serum creati-
nine. For the prediction of no RRT initiation, the AUC-
R O Cc u r v ef o ru r i n eh e p c i d i na ts i xh o u r sw a s0 . 8 1
(Figure 5A). The predictive value at 24 hours remained
essentially unchanged (no AKI: AUC-ROC curve 0.81,
95% CI 0.73 to 0.90; no RRT: 0.77, 95% CI 0.64 to 0.89).
When each RIFLE class was considered, the AUC-
ROC curves for urine hepcidin at six hours were 0.81
for not developing RIFLE R (n =4 )( 9 5 %C I0 . 7 1t o
0.88, sensitivity 75%, specificity 86%, cutoff >120 ng/
mL), 0.81 for not developing RIFLE I (n =3 )( 9 5 %C I
0.72 to 0.89, sensitivity 100%, specificity 62%, cutoff
>460 ng/mL) and 0.75 for not developing RIFLE F (n =
2) (95% CI 0.65 to 0.83, sensitivity 100%, specificity 58%,
cutoff >550 ng/mL).
Urine hepcidin adjusted to urine creatinine
At baseline, urine hepcidin adjusted to urine creatinine
(Table 3) tended to be higher in AKI-free patients. At
six and twenty-four hours after commencement of CPB,
urine hepcidin adjusted to urine creatinine was signifi-
cantly higher in patients not developing AKI (Table 3).
The AUC-ROC curves were 0.88 for predicting an AKI-
free status (Figure 4B) and 0.88 for no RRT initiation
(Figure 5B). At 24 hours, the AUC-ROC curve declined
(no AKI: 0.68, 95% CI 0.50 to 0.87; no RRT: 0.73, 95%
CI 0.53 to 0.92).
Urine creatinine at six hours after CPB alone did not
separate patients with subsequent AKI from those with-
out (Table 3). Changes (from baseline to six hours) in
urine hepcidin levels adjusted to urine creatinine did
not change the predictive value and did not indicate a
carryover effect from baseline to postoperative values,
given a different relative change (Table 4).
Plasma hepcidin
Plasma hepcidin concentrations were three to seven
times lower compared to urine hepcidin in patients not
developing AKI (Figure 3A vs. Figure 2A). At baseline,
patients who did not develop AKI had a mean plasma
hepcidin concentration of 112 ng/mL (range, 78 to 203
ng/mL) compared to 55 ng/mL (range, 50 to 146 ng/
mL) in patients who developed AKI (Figure 3A). Hepci-
din levels at six hours after the start of CPB tripled in
patients who developed AKI (167 ng/mL; range, 73 to
325 ng/mL), whereas they only doubled (261 ng/mL;
range, 154 to 386 ng/mL) in those who remained AKI-
free. Postoperative plasma hepcidin concentration had a
lower AUC-ROC curve than (un)adjusted urine hepcidin
and was not useful in separating patients with or with-
out AKI (Figures 3A and 4C). The same applied to RRT
initiation (Figure 5C).
Table 2 Interventions and outcomes
a
All patients Excluding patients with preoperative CKD
Variables AKI (n = 9) No AKI (n = 91) P
value
AKI (n = 5) No AKI (n = 69) P
value
CABG surgery, n (%) 2 (22.2%) 17 (18.7%) 0.68 1 (20.0%) 13 (18.8%) >0.99
Valve surgery, n (%) 4 (44.5%) 46 (50.5%) >0.99 2 (40.0%) 37 (53.6%) 0.66
CABG and valve surgery, n (%) 3 (33.3%) 21 (23.1%) 0.68 2 (40.0%) 14 (20.3%) 0.29
Thoracic aortic surgery, n (%) 0 (0.0%) 7 (7.7%) >0.99 0 (0.0%) 5 (7.3%) >0.99
Previous cardiothoracic operation, n
(%)
2 (22.2%) 26 (28.6%) >0.99 1 (20.0%) 23 (33.3%) >0.99
Duration of bypass, minutes 125 (100 to 172) 119 (91 to 158) 0.62 109 (80 to 146) 119 (90 to 156) 0.57
Fluid balance
b, mL 4,980 (3,000 to
16,200)
3,100 (1,690 to
4,660)
0.035 4,920 (450 to
16,200)
3,100 (1,260 to
4,800)
0.4
Furosemide
b, n (%) 9 (100%) 84 (92.3%) 0.39 5 (100.0%) 63 (91.3%) >0.99
Furosemide
b, mg 130 (60 to 460) 50 (20 to 90) 0.003 160 (35 to 672) 45 (20 to 70) 0.05
Vasopressor use
b, n (%) 7 (77.8%) 65 (71.4%) 0.69 5 (100.0%) 49 (71.0%) 0.32
Inotrope use
b, n (%) 8 (88.9%) 51 (63.7%) 0.13 4 (80.0%) 45 (65.2%) 0.66
Blood transfusion
b, n (%) 8 (88.9%) 52 (57.1%) 0.06 4 (80.0%) 39 (56.5%) 0.39
Blood transfusion
b, mL 1,000 (500 to 6,380) 500 (0 to 500) 0.005 1,250 (250 to 6,800) 250 (0 to 500) 0.048
LOS in hospital, days 14 (8 to 19) 9 (7 to 14) 0.024 14 (8 to 19) 9 (7 to 14) 0.48
Need for RRT, n (%) 3 (33.3%) 2 (2.2%) 0.005 2 (40.0%) 0 (0.0%) 0.004
Hospital mortality, n (%) 3 (33.3%) 0 (0%) 0.001 1 (20.0%) 0. (0.0%) 0.068
aAKI, acute kidney injury; CKD, chronic kidney disease; CABG, coronary artery bypass graft; LOS, length of stay; RRT, renal replacement therapy. AKI is defined as
Risk, Injury, Failure, Loss, End-stage renal disease classification of AKI (RIFLE) class R or worse including serum creatinine increase and urine output decrease. Data
are medians (25th to 75th percentiles) unless otherwise indicated.
bIncluding intraoperative and 48-hour postoperative values.
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At six hours after commencement of CPB, urine hepci-
din adjusted to urine creatinine (P = 0.016) was the only
independent predictive biomarker for no AKI (Table 5),
and the quality of the model improved considerably
(from R
2 =0 . 4 2t oR
2 = 0.63). Serum creatinine at six
hours after commencement of CPB had no reasonable
AUC-ROC (0.69 [95% CI 0.48 to 0.93]) and was not an
independent predictor of AKI (P > 0.1). Other clinical
predictors (model 0) included age, impaired LVEF,
COPD and PVD and were retained in the models 1
through 3 after inclusion of renal biomarkers (Table 5).
Correlation of urine and plasma hepcidin levels
At baseline, urine hepcidin adjusted to urine creatinine
correlated well with plasma hepcidin (r =0 . 7 6 ,P <
0.001). We found a good correlation between postopera-
tive plasma hepcidin and urine hepcidin in patients not
developing AKI (six hours after CPB: r =0 . 6 2 ,P <
0.001), but no correlation in those with subsequent AKI
(six hours after CPB: r = 0.18, P = 0.64).
Urine/plasma hepcidin ratio and fractional excretion of
hepcidin
In AKI-free patients, a urine/plasma hepcidin ratio >1
was observed, which increased from 2.6 to 6.9 over time
(Table 3). Patients developing AKI, however, presented
w i t hau r i n e / p l a s m ah e p c i d i nr a t i oa r o u n d1 . 0 ,w h i c h
remained stable over time (Table 3). Overall, the highest
FE of hepcidin was detected at six hours after com-
mencement of CPB. However, the FE of hepcidin was
about three times higher in those not developing AKI
(Table 3).
Influence of exclusion of patients with preoperative
chronic kidney disease
The findings at baseline and interventions and out-
comes remained essentially unchanged after patients
with preoperative CKD were excluded from the analyses
(Tables 1 and 2). The magnitude of urine and plasma
hepcidin concentrations and the increase over time or
the predictive values of hepcidin did not differ signifi-
cantly between patients with or without CKD (Table 6).
Also, of note, preoperative urine and plasma hepcidin
levels or the urine/plasma hepcidin ratio did not corre-
late with preoperative eGFR (all r <0 . 2 ,a l lP >0 . 1 )
(Table 7).
Discussion
Key findings
In a control cohort recruited to participate in an inter-
ventional study of AKI after CPB, we found that higher
urine hepcidin concentrations determined early post-
operatively were associated with ruling out AKI, whereas
postoperative hepcidin remained at preoperative levels
in patients with subsequent AKI. Furthermore, early
postoperative urine hepcidin levels and, even more so,
urine hepcidin adjusted to urine creatinine discriminated
patients not developing AKI or not requiring RRT initia-
tion from those who did, although the event rate was
low. Early postoperative urine hepcidin levels adjusted
to urine creatinine were also independent predictors of
ruling out AKI. On the other hand, plasma hepcidin
levels and serum creatinine determined early
Figure 2 Urine hepcidin concentration over time. Patients not
developing acute kidney injury (AKI) (white bars) are compared to
those with AKI (hatched bars) (A) for all patients and (B) after
excluding patients with chronic kidney disease (CKD). Error bars at
top and bottom define th 95% confidence interval and the black
lines within boxes the medians.
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AKI after cardiac surgery. The study findings remained
essentially unchanged after excluding patients with preo-
perative CKD. Preoperative values of urine hepcidin
correlated with plasma hepcidin levels; however, post-
operatively, this correlation was present only in patients
not developing AKI. In patients with AKI, postoperative
urine hepcidin concentrations were three to seven times
Figure 4 Predictive indices of hepcidin at six hours after commencement of CPB for not developing AKI. (A) Urine hepcidin. (B) Urine
hepcidin/urine creatinine. (C) Plasma hepcidin. AUC-ROC, area under the curve receiver operating characteristic curve.
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plasma hepcidin levels.
Relation to previous studies
The incidence of AKI in our patient cohort was similar to
that recently described by Argalious et al. [24] but lower
than that previously reported by Haase et al. [25] in an
Australian cohort. A multitude of studies have investigated
hepcidin in a number of nonrenal diseases, for example, as
a marker of anemia [26-28], but also in CKD [29,30]. Hep-
cidin is a peptide hormone synthesized in hepatocytes and
is detected in the normal kidney, heart and brain [31,32].
Hepcidin is centrally involved in iron homeostasis, and its
synthesis is increased under inflammatory conditions via
interleukin 6. On the other hand, its synthesis is reduced
in the setting of hypoxia [11,26,28,33,34].
In the kidney, systemic hepcidin is filtered through the
glomerulus, partly reabsorbed into the proximal tubules
Figure 5 Predictive indices of hepcidin at six hours for not requiring postoperative renal replacement therapy initiation. (A) Urine
hepcidin. (B) Urine hepcidin/urine creatinine. (C) Plasma hepcidin.
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the kidney, hepcidin is expressed in the apical tubular
epithelium of the thick ascending limb of the loop of
Henle [13]. Preoperative serum hepcidin concentrations
were similar to those reported in five cardiac surgery
patients [35] as well as in healthy adults [20]. Also, in a
previous study, urine hepcidin levels adjusted to urine
creatinine and plasma hepcidin concentrations corre-
lated well in healthy individuals [20], as seen preopera-
tively in our cohort.
Using mass spectroscopy, Ho et al. [14] detected a
urine hepcidin peak with increased frequency and
intensity on the first postoperative day in patients with
a postoperative serum creatinine increase <10% from
baseline to peak compared to patients with AKI. This
hypothesis-generating approach maximized the
likelihood of detecting a signal but may not be general-
ized to consecutive patients. Also, hepcidin assays
based on mass spectroscopy techniques [36] are semi-
quantitative and depend on expensive equipment that
is not widely available. Therefore, the authors sug-
gested that quantification of hepcidin in both plasma
and urine samples in consecutive patients would be
necessary to elucidate the potential diagnostic and
prognostic value of hepcidin for AKI after cardiopul-
monary bypass [37]. None of the studies reported the
quantitative measurement of plasma and urine hepci-
din levels as renal biomarkers in patients at risk of
AKI after CPB. Our findings are consistent with those
reported by Ho et al. [14]. By contrast, our results
deviate from those observed in a small patient cohort
[38] describing no association between postoperative
Table 3 Perioperative hepcidin indices
a
All patients Excluding patients with preoperative CKD
Hepcidin index No AKI (n = 91) AKI (n =9 ) P value No AKI (n = 69) AKI (n =5 ) P value
Urine hepcidin/urine creatinine, ng/mg
Baseline 308 (122 to 583) 120 (34 to 295) 0.07 309 (143 to 570) 164 (100 to 633) 0.6
6 hours after CPB start 5,175 (2,086 to 9,539) 1,229 (314 to 2,379) <0.001 5,402 (2,100 to 9,300) 1,400 (639 to 2,379) 0.009
24 hours after CPB start
b 3,255 (1,576 to 6,652) 1,345 (537 to 3,583) 0.07 3,143 (1,798 to 6,585) 1,345 (971 to 3,362) 0.06
Friedman test <0.001 0.005 <0.001 0.11
Urine creatinine, mg/mL
Baseline 1.14 (0.57 to 1.74) 0.92 (0.51 to 1.83) 0.52 1.28 (0.60 to 1.96) 1.66 (0.78 to 2.10) 0.71
6 hours after CPB start 0.19 (0.10 to 0.28) 0.21 (0.10 to 0.30) 0.84 0.19 (0.11 to 0.28) 0.21 (0.12 to 0.30) 0.97
24 hours after CPB start
b 0.46 (0.24 to 0.71) 0.22 (0.12 to 0.29) 0.008 0.52 (0.29 to 0.73) 0.22 (0.18 to 0.37) 0.022
Friedman test <0.001 0.03 <0.001 0.17
Urine/plasma hepcidin ratio
Baseline 2.6 (1.2 to 4.9) 1.1 (0.2 to 5.6) 0.18 2.8 (1.2 to 4.8) 4.6 (1.6 to 8.4) 0.41
6 hours after CPB start 3.1 (1.5 to 5.3) 1.0 (0.2 to 3.1) 0.047 3.6 (1.9 to 5.9) 3.0 (1.0 to 46.7) 0.59
24 hours after CPB start
b 6.9 (2.0 to 13.3) 1.2 (0.6 to 2.4) 0.011 8.2 (3.8 to 15.1) 2.3 (0.8 to 11.6) 0.11
Friedman test <0.001 0.69 <0.001 0.74
Fractional hepcidin excretion, %
Baseline 2.4 (1.5 to 4.1) 1.7 (0.7 to 2.5) 0.17 2.3 (1.5 to 2.9) 2.5 (1.8 to 4.7) 0.58
6 hours after CPB start 22.1 (12.2 to 30.0) 8.3 (1.7 to 19.5) 0.005 22.0 (15.1 to 30.5) 16.3 (3.6 to 22.5) 0.19
24 hours after CPB start
b 14.7 (9.5 to 25.2) 8.1 (4.5 to 46.5) 0.35 15.3 (9.9 to 25.2) 8.1 (5.1 to 55.7) 0.6
Friedman test <0.001 0.021 <0.001 0.47
aAKI, acute kidney injury; CKD, chronic kidney disease; CPB; cardiopulmonary bypass. AKI is defined as Risk, Injury, Failure, Loss, End-stage renal disease
classification of AKI (RIFLE) class R or worse including serum creatinine increase and urine output decrease. Data are medians (25th to 75th percentiles) unless
otherwise indicated.
bValues at 24 hours after CPB start refer to 89 patients without AKI and 9 patients with AKI.
Table 4 Changes in urine hepcidin levels adjusted to urine creatinine
a
Urine hepcidin/urine creatinine AKI (n = 9) No AKI (n = 91) P value
Δ 6 to 0 hours, ng/mg 1,079 (85 to 2,195) 4,085 (1,998 to 8,736) <0.001
Δ 6 to 0 hours, % 626 (108 to 1,541) 1,444 (867 to 3,269) 0.016
Δ 24 to 0 hours, ng/mg 1,142 (344 to 3,379) 2,821 (1,266 to 6,482) 0.119
Δ 24 to 0 hours, % 925 (270 to 1,825) 939 (338 to 2,458) 0.717
Δ 24 to 6 hours, ng/mg 325 (-397 to 1,959) -1,051 (-4,350 to 1,531) 0.079
Δ 24 to 6 hours, % 139 (-29 to 235) -33 (-71 to 71) 0.02
aAKI, acute kidney injury. Data are medians (25th to 75th percentiles). Urine hepcidin/urine creatinine 6 hours to 0 hours for AKI: area under the curve receiver
operating characteristic curve 0.88 (0.79 to 0.98) (P < 0.001), sensitivity 75%, specificity 87%, cutoff 1,320 ng/mg.
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postoperative day.
Significance of study findings
As a low-molecular-weight peptide (2.78 kDa), hepcidin
would be expected to pass unimpeded into the glomeru-
lar ultrafiltrate with a sieving coefficient of 1. However,
at baseline, we found a low fractional excretion of hepci-
din, implying significant tubular reabsorption and/or
catabolism of hepcidin along the nephron. Markedly
increased postoperative fractional excretion of hepcidin
(10-fold) in patients not developing AKI may point
toward (1) relatively preserved filtration, (2) reduced or
saturated reabsorption, (3) increased active secretion
and (4) increased local synthesis of hepcidin along the
nephron [13], or any combination of these factors.
Many studies [39-41] have suggested that there is
tubular injury with CPB [3]. Thus one might expect that
reduced hepcidin absorption alone would be greater in
patients who subsequently develop AKI, resulting in
higher urine hepcidin concentrations. The fact that the
opposite occurs makes this mechanism less likely. As
active hepcidin secretion has not been demonstrated
previously, this mechanism also seems less likely. Rela-
tively preserved filtration in the setting of a simulta-
neous decrease in reabsorption, however, seems possible
and more likely. Decreased reabsorption would explain
an increase in urine hepcidin levels for all patients.
Later on, relatively preserved filtration (reflecting better
GFR) would be expected to further elevate urine hepci-
din concentrations in recovering patients and thereby
identify those at lower risk of subsequent AKI.
Loss of integrity of tubular tight junctions with tubular
backleak of urine hepcidin would explain a postopera-
tive increase in plasma concentrations in patients devel-
oping AKI, but not its observed low magnitude. Also,
one would expect hepcidin and creatinine to backleak
equally, unless hepcidin was then sequestered or less
was delivered downstream. Finally, the additional role of
local hepcidin release remains unknown, and upregula-
tion of tubular hepcidin [13], as is the case for lipocalin
2 [42], may be an adaptive response to injury. Hepcidin-
mediated intracellular iron sequestration may act to
limit ischemia-reperfusion injury in a manner analogous
to exogenous deferoxamine administration [14]. Irre-
spective of the underlying mechanisms, measurement of
urine hepcidin concentrations, combined with measure-
ments of one or more other biomarkers (that is, lipoca-
lin 2), may provide additional information for the early
identification of individuals who will or will not develop
AKI.
Strengths and limitations
To the best of our knowledge, this study is the first to
describe in detail the relationship between urine and
plasma hepcidin and AKI in humans after CPB. We
used a novel competitive enzyme-linked immunoassay
for human hepcidin [20] which accurately and reprodu-
cibly detects physiologic and pathologic changes in
plasma or urine hepcidin levels. We simultaneously
measured both plasma and urine hepcidin levels to elu-
cidate whether there is an interrelationship between
them.
However, we focused on a single renal biomarker
(hepcidin) involved in complex traits of iron metabo-
lism. Our findings are limited to a single-center study,
and center-specific effects cannot be excluded. Although
in our study the event rate was low, the findings were
consistent with those of a previous publication [14] and
with those of another independent observational study
[43]. Our study appears to be underpowered for the
Figure 3 Plasma hepcidin concentration over time. Patients not
developing AKI (white bars) are compared to those with AKI
(hatched bars) (A) for all patients and (B) after excluding patients
with CKD. Error bars at top and bottom define th 95% confidence
interval and the black lines within boxes the medians.
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Page 10 of 13Table 5 Multivariate logistic regression analysis (all patients) of risk factors and biomarkers at six hours after CPB
start for the prediction of no AKI
a
Model 0 (R
2 = 0.42) Model 1 (R
2 = 0.63) Model 2 (R
2 = 0.43) Model 3(R
2 = 0.50)
Risk factors and
biomarkers
Regression
coefficient (B) (SE)
P
value
Regression
coefficient (B) (SE)
P
value
Regression
coefficient (B) (SE)
P
value
Regression
coefficient (B) (SE)
P
value
Age, years -0.2 (0.1) 0.015 -0.2 (0.1) 0.06 -0.1 (0.1) 0.06 -0.2 (0.1) 0.036
LVEF <35% -2.9 (1.1) 0.009 -4.1 (1.6) 0.008 -2.7 (1.1) 0.011 -3.0 (1.2) 0.01
COPD -2.2 (1.0) 0.036 -2.4 (1.3) 0.06 -2.0 (1.0) 0.044 -2.5 (1.1) 0.026
Log urine hepcidin/urine
creatinine, ng/mg
2.9 (1.1) 0.011
Log urine hepcidin, ng/mL 1.2 (0.7) 0.09
Log plasma hepcidin,
ng/mL
2.7 (2.5) 0.56
aAKI, acute kidney injury; CPB, cardiopulmonary bypass; LVEF, left ventricular ejection fraction; COPD, chronic obstructive pulmonary disease; SE, standard error.
Variables tested on univariate relation with incidence of acute kidney injury (AKI) included all variables displayed in Table 1, type and duration of surgery and
renal biomarkers at six hours after start of CPB. Multivariate logistic regression analysis included relevant variables for (no) AKI with univariate P value <0.1 (age,
atrial fibrillation, LVEF <35%, COPD and peripheral vascular disease). Variables were presented in model 0 if their multivariate P value was <0.05 (age, LVEF <35%
and COPD). We included each biomarker one after another (models 1 through 3) into multivariate regression analysis to exclude interaction.
Table 6 Predictive values of biomarkers for ruling out AKI excluding patients with preoperative CKD
a
Biomarkers AUC-ROC (95% CI) Sensitivity Specificity Cutoff
Urine hepcidin, ng/mL
6 hours after CPB start 0.81 (0.67 to 0.96) 62.30% 100.00% >545
24 hours after CPB start 0.83 (0.74 to 0.92) 79.70% 100.00% >475
Urine hepcidin/urine creatinine, ng/mg
6 hours after CPB start 0.87 (0.75 to 0.99) 70.00% 100.00% >2820
24 hours after CPB start 0.75 (0.57 to 0.94) 76.50% 80.00% >1,762
Plasma hepcidin, ng/mL
6 hours after CPB start 0.70 (0.46 to 0.98) 69.00% 80.00% >175
24 hours after CPB start 0.54 (0.23 to 0.86) N/A N/A N/A
aAKI, acute kidney injury; AUC, area under the curve; ROC, receiver operating characteristic; CKD, chronic kidney disease; CPB; cardiopulmonary bypass; N/A,
values not presented for AUC-ROC <0.6. AKI is defined as Risk, Injury, Failure, Loss, End-stage renal disease classification of AKI (RIFLE) class R or worse including
serum creatinine increase and urine output decrease.
Table 7 Correlation coefficients of hepcidin with preoperative eGFR
a
Baseline variables Spearman’s r Preoperative eGFR
Urine hepcidin Correlation coefficient 0.15
Significance (two-sided) 0.15
Number of patients 100
Urine hepcidin adjusted to urine creatinine Correlation coefficient 0.07
Significance (two-sided) 0.51
Number of patients 100
Plasma hepcidin Correlation coefficient 0.043
Significance (two-sided) 0.67
Number of patients 100
Urine/plasma hepcidin ratio Correlation coefficient 0.16
Significance (two-sided) 0.11
Number of patients 100
aeGFR, estimated glomerular filtration rate.
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Page 11 of 13detection of a preoperative difference in hepcidin levels.
AKI after CPB has specific etiopathologic factors, and
these findings may not be generalized to AKI in other
contexts. Furthermore, proof of association does not
imply that hepcidin is causatively involved in the patho-
genesis of or response to AKI after CPB.
Future studies
Our study findings suggest the need to investigate the
role and source of urine hepcidin in the pathophysiology
of AKI after cardiac surgery using CPB. Such investiga-
tions may encompass interventions such as the modula-
tion of iron release and disposal during CPB. In
addition, it now seems desirable to investigate the diag-
nostic and prognostic values of hepcidin in other forms
of AKI as well as the combined diagnostic and prognos-
tic value of hepcidin in conjunction with other
biomarkers.
Conclusions
Our findings suggest that early postoperative urine hep-
cidin determination has additive value in ruling out AKI
after CPB, thereby potentially helping to triage patients.
The nature of this association, the central biological role
of hepcidin in iron metabolism and the possible impor-
tance of iron in the pathogenesis of CPB-associated
AKI, taken together, identify hepcidin as an interesting
subject for future research in this context.
Key messages
￿ Cardiopulmonary bypass increases plasma and
urine hepcidin levels.
￿ The increase in urinary hepcidin levels is greater in
patients who do not develop AKI.
￿ Urine hepcidin has additive value in ruling out
acute kidney injury in patients after cardiac surgery.
￿ Urine hepcidin is predictive of not needing post-
operative RRT.
￿ Plasma hepcidin does not rule out the develop-
ment of acute kidney injury.
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